Apellis Pharmaceuticals Inc (APLS)
$39.75
+0.87
(+2.24%)▲
Performance
- $38.00$39.95$39.75
4.4%
Downside
Day's Volatility :4.88%
Upside
0.5%
- $19.83$73.80$39.75
50.11%
Downside
52 Weeks Volatility :73.13%
Upside
46.14%
Returns
| Period | Apellis Pharmaceuticals Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -22.02% | 6.5% | 0.0% |
6 Months | -39.29% | 7.1% | 0.0% |
1 Year | 21.69% | 9.8% | 0.0% |
3 Years | -41.76% | 14.2% | -20.2% |
Highlights
Market Capitalization | 4.7B |
Book Value | $2.2 |
Earnings Per Share (EPS) | -3.57 |
Wall Street Target Price | 74.94 |
Profit Margin | -79.62% |
Operating Margin TTM | -36.03% |
Return On Assets TTM | -27.9% |
Return On Equity TTM | -122.94% |
Revenue TTM | 524.1M |
Revenue Per Share TTM | 4.33 |
Quarterly Revenue Growth YOY | 284.3% |
Gross Profit TTM | 69.8M |
EBITDA | -402.3M |
Diluted Eps TTM | -3.57 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.03 |
EPS Estimate Next Year | 0.91 |
EPS Estimate Current Quarter | -0.52 |
EPS Estimate Next Quarter | -0.37 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 88.53%
Technicals Summary
Sell
Neutral
Buy
Apellis Pharmaceuticals Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Apellis Pharmaceuticals Inc | -3.83% | -39.29% | 21.69% | -41.76% | 35.19% |
 Moderna, Inc. | -1.67% | 18.26% | -0.21% | -64.15% | 752.69% |
 Regeneron Pharmaceuticals, Inc. | -0.46% | 13.21% | 45.59% | 84.19% | 244.2% |
 Novo Nordisk A/s | -11.0% | 18.31% | 61.56% | 186.46% | 423.59% |
 Vertex Pharmaceuticals Incorporated | 3.85% | 14.43% | 39.88% | 147.45% | 195.07% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Apellis Pharmaceuticals Inc | NA | NA | NA | -1.03 | -1.23 | -0.28 | NA | 2.2 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.19 | -0.38 | -0.16 | NA | 33.47 |
Regeneron Pharmaceuticals, Inc. | 31.35 | 31.35 | 1.46 | 44.44 | 0.15 | 0.08 | NA | 250.15 |
Novo Nordisk A/s | 44.28 | 44.28 | 2.36 | 3.43 | 1.0 | 0.25 | 0.01 | 22.18 |
Vertex Pharmaceuticals Incorporated | 31.85 | 31.85 | 0.53 | 16.98 | 0.24 | 0.13 | NA | 71.8 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Apellis Pharmaceuticals Inc | Buy | $4.7B | 35.19% | NA | -79.62% |
Moderna, Inc. | Buy | $45.3B | 752.69% | 24.73 | -115.82% |
Regeneron Pharmaceuticals, Inc. | Buy | $116.9B | 244.2% | 31.35 | 29.45% |
Novo Nordisk A/s | Buy | $572.0B | 423.59% | 44.28 | 36.55% |
Vertex Pharmaceuticals Incorporated | Buy | $126.7B | 195.07% | 31.85 | 39.46% |
Insights on Apellis Pharmaceuticals Inc
Increasing Revenue
Revenue is up for the last 9 quarters, 14.38M → 172.32M (in $), with an average increase of 24.3% per quarter
Increasing Net Profit
Netprofit is up for the last 3 quarters, -140.23M → -66.42M (in $), with an average increase of 45.8% per quarter
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 39.9%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 228.3%
Institutional Holdings
Wellington Management Company LLP
12.41%EcoR1 Capital, LLC
9.36%venBio Select Advisor LLC
9.16%Vanguard Group Inc
7.83%BlackRock Inc
4.53%T. Rowe Price Investment Management,Inc.
3.79%
Corporate Announcements
Apellis Pharmaceuticals Inc Earnings
Apellis Pharmaceuticals Inc’s price-to-earnings ratio stands at None
Read More
Company Information
apellis pharmaceuticals is an early stage biotechnology company applying immunotherapy to auto-immune diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease (copd), diseases of the retina such as age-related macular degeneration (amd), and rare hematological diseases such as paroxysmal nocturnal hemoglobinuria (pnh). apellis believes that targeting a key element in the immune system called the complement system can have profound disease modifying benefits. we call this approach complement immunotherapy.
Organization | Apellis Pharmaceuticals Inc |
Employees | 702 |
CEO | Dr. Cedric Francois M.D., Ph.D. |
Industry | Distribution Services |
